ArticleThe Journal of membrane biology2025
Design of a Multi-Epitope Vaccine using β-barrel Outer Membrane Proteins Identified in Chlamydia trachomatis.
Article in The Journal of membrane biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pangenome-Guided Reverse Vaccinology and Immunoinformatics Approach for Rational Design of a Multi-Epitope Subunit Vaccine Candidate Against the Multidrug-Resistant PathogenPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlamydia trachomatis is an obligate intracellular Gram-negative pathogen that causes sexually transmitted infections (STIs) and trachoma. Current interventions are limited due to the widespread nature of asymptomatic infections, and the absence of a licensed vaccine exacerbates the challenge. In this study, we predicted outer membrane β-barrel (OMBB) proteins and designed a multi-epitope vaccine (MEV) construct using identified proteins. We employed a consensus-based computational framework on the C. trachomatis D/UW-3/CX proteome and identified 17 OMBB proteins, including well-known Pmp family members and MOMP. Eight OMBB proteins were computationally characterized, showing significant structural homology with known outer membrane proteins from other bacteria. Sequence-based annotation tools were used to determine their putative functions. B-cell and T-cell epitopes were predicted from the selected proteins. The MEV construct was designed using four cytotoxic T-lymphocyte (CTL) epitopes and 29 helper T-lymphocyte (HTL) epitopes from six OMBB proteins, which were conserved across 106 C. trachomatis serovars. To enhance its immunogenicity, the vaccine was supplemented with the Cholera toxin B subunit and PADRE sequence at the N-terminus. The MEV construct, of length 780 amino acids, was predicted to be antigenic, non-allergenic, non-toxic, and soluble. Secondary structure analysis revealed 95% random coils. A three-dimensional structural model of the MEV was generated and subsequently validated. Molecular docking between MEV and toll-like receptor 4 (TLR4) revealed strong and stable binding interactions. The MEV-TLR4 complex was found to be structurally compact and stable using molecular dynamics simulation. Immune simulation of the MEV construct elicited a strong immune response. This study highlights OMBB proteins as promising immunogenic targets and presents a computationally designed MEV candidate for C. trachomatis infection.
Indexed as
Identifiers
40906223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.